TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Marksans Pharma Limited ( (IN:MARKSANS) ) has provided an announcement.
Marksans Pharma Limited has announced an upgrade in its credit rating by India Ratings and Research. The company’s long-term debt rating has been improved to ‘IND AA-‘ from ‘IND A+’ with a stable outlook, while its short-term debt rating has been affirmed at ‘IND A1+’. This upgrade reflects positively on the company’s financial stability and could enhance its reputation and borrowing capacity in the market.
More about Marksans Pharma Limited
Marksans Pharma Limited operates in the pharmaceutical industry, focusing on the development, manufacture, and marketing of generic pharmaceutical formulations. The company is known for its wide range of products catering to various therapeutic segments, with a strong presence in both domestic and international markets.
YTD Price Performance: -34.38%
Average Trading Volume: 105,679
Current Market Cap: 90.61B INR
For a thorough assessment of MARKSANS stock, go to TipRanks’ Stock Analysis page.